Journal ArticleDOI
Protocole homéopathique d’accompagnement des inhibiteurs oraux des kinases dépendantes des cyclines 4 et 6 (CDK 4/6), dans le cancer du sein post-ménopausique métastatique hormonodépendant
Reads0
Chats0
TLDR
Dans notre experience, le traitement de support homeopathique permet d’eviter l’espacement des cures, the reduction of the posologie et represente un gain of chances pour les patientes.About:
This article is published in La Revue d'Homéopathie.The article was published on 2019-12-01. It has received 1 citations till now.read more
Citations
More filters
Journal ArticleDOI
Prévention et traitement des effets secondaires des inhibiteurs de la poly-ADP-ribose-polymérase-1 (iPARP) dans les cancers du sein et de l’ovaire
TL;DR: In this paper, the authors discuss the use of poly-ADP-ribose polymerase (iPARP) dynamisees in the context of cancer treatment and propose a method to reduce the secondaires of cancer cellules.
References
More filters
Journal ArticleDOI
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
José Baselga,Mario Campone,Martine Piccart,Howard A. Burris,Hope S. Rugo,Tarek Sahmoud,Shinzaburo Noguchi,Michael Gnant,Kathleen I. Pritchard,Fabienne Lebrun,J. Thaddeus Beck,Yoshinori Ito,Denise A. Yardley,Ines Deleu,Alejandra T. Perez,Thomas Bachelot,L. Vittori,Zhiying Xu,Pabak Mukhopadhyay,David Lebwohl,Gabriel N. Hortobagyi +20 more
TL;DR: Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromat enzyme inhibitors.
Journal ArticleDOI
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn,Miguel Martin,Hope S. Rugo,Stephen R. Jones,Seock-Ah Im,Karen A. Gelmon,Nadia Harbeck,Oleg Lipatov,Janice M. Walshe,Stacy L. Moulder,Eric Gauthier,Dongrui R. Lu,Sophia Randolph,Véronique Diéras,Dennis J. Slamon +14 more
TL;DR: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with let rozole alone, although the rates of myelotoxic effects were higher with palbokiclib-letrozoles.
Journal ArticleDOI
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,Mario Campone,Katarína Petráková,Kimberly L. Blackwell,Eric P. Winer,Wolfgang Janni,Sadaanand Verma,Pierfranco Conte,Carlos L. Arteaga,David Cameron,S. Mondal,Fei Su,Michelle Miller,Mohamed Elmeliegy,C. Germa,Joyce O'Shaughnessy +20 more
TL;DR: Improved efficacy outcomes and manageable tolerability observed with first-line ribociclib plus letrozole monotherapy are maintained with longer follow-up, relative to letrozo monotherapy.
Journal ArticleDOI
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Thomas J. Raub,Graham N. Wishart,Palaniappan Kulanthaivel,Brian A. Staton,Rose T. Ajamie,Geri A. Sawada,Lawrence M. Gelbert,Harlan E. Shannon,Concepcion Sanchez-Martinez,Alfonso De Dios +9 more
TL;DR: Data show that abemaciclib crosses the blood–brain barrier and confirm that both CDK4 and CDK6 inhibitors reach unbound brain levels in rodents that are expected to produce enzyme inhibition; however, abemACiclib brain levels are reached more efficiently at presumably lower doses than palbociclib and are potentially on target for a longer period of time.
Journal ArticleDOI
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Hope S. Rugo,Véronique Diéras,Karen A. Gelmon,Richard S. Finn,DJ Slamon,Miguel Martin,Patrick Neven,Yaroslav Shparyk,A. Mori,D. Lu,H. Bhattacharyya,Cynthia Huang Bartlett,Shrividya Iyer,S.R.D. Johnston,Johannes Ettl,Nadia Harbeck +15 more
TL;DR: Overall, women with MBC receiving first-line endocrine therapy have a good QOL, and the addition of palbociclib to letrozole maintains health-related QOL and improves pain scores in treatment-naïve postmenopausal patients with ER+/HER2− MBC compared with letroZole alone.